Researchers at the University of Cambridge have engineered a novel vaccine using Artificial Intelligence, marking the first instance of a vaccine component designed entirely by AI. This vaccine aims to provide protection against all coronaviruses and potentially prevent future pandemics. The initial trials, which included 39 participants, assessed the vaccine's safety and observed a 'modest' immune response. The AI developed a 'super-antigen' capable of training the immune system to recognize various coronaviruses, adapting to mutations and new infections. Excited by the preliminary results, the team plans to conduct a larger trial with 200 participants for a more comprehensive evaluation. Additionally, the researchers are investigating vaccines for other viruses, such as influenza and Ebola, and are conducting animal studies for universal flu vaccines that wouldn't require annual updates. Prof. Marian Knight from the National Institute for Health and Care Research emphasized the trial's success as a pivotal advancement in the quest for broad, lasting viral protection.